ClinicalTrials.gov
public full text
Public Domain
Atogepant in Real Life in Italy (GIANT)
Atogepant is an oral, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist that has been approved for the preventive treatment of episodic and chronic migraine (\>= 4 monthly migraine days) with or without medication overuse.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients#901017
- Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events#845432
- Italy – Miscellaneous medical devices and products – 26PRE013 CUC - PRODOTTI VARI PER DIABETOLOGIA DPC — Centrale Unica di Commitenza (CUCSA FVG) (ITA) · 3371175 EUR#1021056
- A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist#906108
- Bion for Occipital Nerve Stimulation#868687
Record · ID 841213
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive